ChemMedChem 2018-04-17

Identifying Small‐Molecule Binding Sites for Epigenetic Proteins at Domain–Domain Interfaces

David Bowkett; Romain Talon; Cynthia Tallant; Chris Schofield; Frank von Delft; Stefan Knapp; Gordon Bruton; Paul E. Brennan

Index: 10.1002/cmdc.201800030

Full Text: HTML

Abstract

Epigenetics is a rapidly growing field in drug discovery. Of particular interest is the role of post‐translational modifications to histones and the proteins that read, write, and erase such modifications. The development of inhibitors for reader domains has focused on single domains. One of the major difficulties of designing inhibitors for reader domains is that, with the notable exception of bromodomains, they tend not to possess a well‐enclosed binding site amenable to small‐molecule inhibition. As many of the proteins in epigenetic regulation have multiple domains, there are opportunities for designing inhibitors that bind at a domain–domain interface which provide a more suitable interaction pocket. Examination of X‐ray structures of multiple domains involved in recognising and modifying post‐translational histone marks using the SiteMap algorithm identified potential binding sites at domain–domain interfaces. For the tandem plant homeodomain–bromodomain of SP100C, a potential inter‐domain site identified computationally was validated experimentally by the discovery of ligands by X‐ray crystallographic fragment screening.

Latest Articles:

Fluorinated GluN2B Receptor Antagonists with a 3‐Benzazepine Scaffold Designed for PET Studies

2018-04-17

[10.1002/cmdc.201700819]

Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone‐Based Cannabinoid Receptor Type 2 Ligands

2018-04-16

[10.1002/cmdc.201800152]

Discovery of Benzimidazole–Quinolone Hybrids as New Cleaving Agents toward Drug‐Resistant Pseudomonas aeruginosa DNA

2018-04-16

[10.1002/cmdc.201700739]

Transthyretin Mimetics as Anti‐β‐Amyloid Agents: A Comparison of Peptide and Protein Approaches

2018-04-16

[10.1002/cmdc.201800031]

Antibody Epitope of Human α‐Galactosidase A Revealed by Affinity Mass Spectrometry: A Basis for Reversing Immunoreactivity in Enzyme Replacement Therapy of Fabry Disease

2018-04-16

[10.1002/cmdc.201800094]

More Articles...